Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Haemoglobin electrophoresis and carrier counselling

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Haemoglobin analysis is rarely an emergency test. Do not delay treatment of suspected sickle crisis, acute chest syndrome, severe anaemia or newborn illness while awaiting fractionation. In pregnancy, however, a result suggesting a clinically important carrier state needs prompt partner testing and screening-team referral because the window for diagnostic options is time limited.

Purpose and principles

Select and interpret haemoglobin analysis in context, recognise assay and transfusion limitations, confirm consequential variants molecularly, and translate paired results into non-directive reproductive counselling.

Haemoglobin separation identifies proteins by charge or retention characteristics. It measures relative fractions but does not directly read the globin genes. HPLC can quantify HbA2 and reveal characteristic retention windows; capillary electrophoresis separates by electrophoretic mobility. A credible laboratory uses complementary methods when a peak is uncertain. The clinician supplies age, ancestry, pregnancy, transfusion, iron status and the suspected condition because the same percentage can mean different things in a newborn, a recently transfused adult or a patient receiving regular exchange.

Interpretation is pattern based. HbA with a smaller HbS fraction often indicates sickle trait, while absent HbA can occur in sickle anaemia or HbS/beta-zero thalassaemia and needs MCV, HbA2, HbF and genomic context. HbE may co-elute with HbA2 on some systems. Raised HbF occurs in infancy, pregnancy, hereditary persistence, marrow stress and treatment with hydroxycarbamide. A normal adult pattern cannot exclude alpha-thalassaemia, and an unexpectedly low HbA2 during iron deficiency may obscure beta trait.

Indications, selection and cautions

Beta-trait pattern

Microcytosis with raised HbA2 and preserved HbA usually supports beta-thalassaemia trait after iron and analytical confounders are considered.

Sickle trait pattern

HbA exceeds HbS in an untransfused adult with otherwise compatible indices, but exact interpretation excludes coexisting beta-thalassaemia or another variant.

No HbA pattern

Absent adult HbA in an untransfused person raises homozygous or compound disease and requires clinical and molecular resolution, not a generic carrier label.

Mixed donor pattern

Multiple small or unexpected fractions after transfusion can reflect donor cells; pre-transfusion results and genotyping prevent false inheritance conclusions.

Time-critical pregnancy resultRed flag

A pregnant carrier whose partner is untested needs prompt screening coordination so fetal-risk assessment and options are not delayed.

Method and interpretation

  1. 01
    Full blood count and red-cell indicesFirst step
    Why
    Provide globin-production context for the fraction pattern.
    Interpretation and limitations
    Low MCV or MCH supports thalassaemia or iron deficiency; normal indices do not exclude sickle or other structural carrier states.
  2. 02
    Ferritin with inflammatory context
    Why
    Identify iron deficiency that can mimic trait indices or lower HbA2.
    Interpretation and limitations
    Correct proven deficiency and repeat an equivocal beta-trait study when needed; do not delay time-critical partner testing in pregnancy.
  3. 03
    HPLC
    Why
    Separate and quantify common haemoglobin fractions and variant windows.
    Interpretation and limitations
    Retention windows suggest identities but co-elution occurs; HbA2 quantification depends on platform and coexisting variants.
  4. 04
    Capillary electrophoresis
    Why
    Provide complementary separation by charge and mobility.
    Interpretation and limitations
    A discordant or unusual band requires laboratory review and sometimes a second method rather than visual naming by the requester.
  5. 05

Clinical next steps

01Test selectionStart with the clinical questionFirst stepMicrocytosis, haemolysis, family history, pregnancy or newborn screening raises haemoglobinopathy.+
  1. 1Provide age, pregnancy, transfusion date, hydroxycarbamide exposure, full count and iron status to the accredited laboratory.
  2. 2Use quantitative haemoglobin separation rather than a solubility screen for carrier or disease classification and retain any pre-transfusion sample.
  3. 3Request complementary analysis or molecular testing when alpha trait, co-elution, compound heterozygosity or reproductive risk cannot be resolved by the initial platform.
02Pattern interpretationRead fractions as a systemA haemoglobin fraction report contains a raised, absent or unexpected peak.+
  1. 1Check whether HbA should be present for age and transfusion status, then integrate HbA2, HbF, variant proportions and red-cell indices.

Risks, monitoring and follow-up

  • Record the analytical method, fractions, red-cell indices, iron status and transfusion timing with the interpreted diagnosis.
  • Ensure confirmatory molecular results replace provisional labels in primary care, maternity and patient-held records.
  • Track partner-testing completion and fetal-medicine referral rather than assuming a carrier leaflet closes the antenatal pathway.
  • Repeat testing after iron replacement or sufficient transfusion washout only when the unresolved result would change clinical care.
  • For newborn results verify confirmatory sampling, paediatric haemoglobinopathy review and parental testing through the screening programme.
  • Revisit counselling when a partner, pregnancy or molecular classification changes, because reproductive probability is genotype specific.

Special situations

Protein test is not DNA

A fraction pattern measures expressed haemoglobin, so silent alpha deletions and co-migrating variants can require molecular resolution.

Donor cells tell another genome

After transfusion the circulating haemoglobin includes someone else's red cells, making timing and pre-transfusion samples critical.

HbA2 has confounders

Iron deficiency and analytical overlap can shift the fraction used to recognise beta trait, so borderline values deserve context.

Counselling is paired

A carrier result alone does not define fetal disease risk; the partner's exact globin genotype completes the calculation.

Common pitfalls

  1. 01

    Excluding alpha trait after normal electrophoresis.

  2. 02

    Interpreting a post-transfusion fraction as native genotype.

  3. 03

    Using sickle solubility to distinguish trait from disease.

  4. 04

    Calling a co-eluting peak definitively without confirmation.

  5. 05

    Giving iron for carrier microcytosis without deficiency.

  6. 06

    Delaying partner testing until late pregnancy.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Normal fractions and alpha trait

A pregnant adult has persistent microcytosis, normal ferritin and normal HPLC fractions. Their partner has an alpha-zero thalassaemia deletion. Which investigation best resolves fetal risk?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS antenatal screening laboratory handbookTesting algorithms, HbA2 interpretation, partner testing and pregnancy timelines.
  • NHS newborn screening laboratory handbookInfant fraction patterns, confirmatory testing and referral.
  • NHS Sickle Cell and Thalassaemia screening collectionNational programme standards and patient-facing carrier pathways.
  • Genomics Education haemoglobinopathy testing resourceProtein and genomic test selection and inheritance interpretation.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Counselling begins only after technical uncertainty is acknowledged. Explain the named variant, whether it represents carrier or disease, health implications for the individual and what partner result would create an affected pregnancy. Avoid saying a couple is simply compatible or incompatible. Show the Mendelian probability for each pregnancy from their exact genotypes and discuss choices without recommending one reproductive outcome. Offer confirmatory molecular testing where phenotype or fetal risk depends on a variant that protein methods cannot resolve.

Key points

  • Modern laboratories use high-performance liquid chromatography, capillary electrophoresis, isoelectric focusing or complementary methods; the report must be interpreted with method, age and clinical question.
  • Adult haemoglobin A predominates normally, with small HbA2 and HbF fractions; newborns predominantly express HbF, so infant patterns use different algorithms.
  • Raised HbA2 supports beta-thalassaemia trait, but iron deficiency, transfusion, delta-chain variants and coexisting haemoglobin variants can alter the result.
  • Alpha-thalassaemia trait often has normal adult fractions and cannot be excluded by a normal electrophoresis or HPLC report.
  • Recent transfusion introduces donor haemoglobins and can dilute or create peaks; document the date, number of units and pre-transfusion sample availability.
  • Sickle solubility tests cannot distinguish trait from disease, are unreliable in newborns or after transfusion, and should not replace quantitative fractionation.
  • Some variants co-elute or migrate together, so the laboratory may need a second analytical platform and targeted molecular confirmation before counselling.
  • Interpret fractions alongside full count, MCV, MCH, ferritin, haemolysis, family history and ethnicity as one clue rather than a biological diagnosis by ancestry.
Globin-gene molecular analysis
Why
Confirm unresolved, clinically significant or reproductively important variants.
Interpretation and limitations
Target alpha deletion, HBB sequencing or broader panels to the question; variants need accredited classification and genetics correlation.
  • 06
    Parental or partner studies
    Why
    Resolve inheritance and calculate fetal risk.
    Interpretation and limitations
    Test each person directly; family report or assumed ethnicity cannot substitute for count, protein analysis and molecular confirmation where needed.
  • 07
    Newborn screening result
    Why
    Identify patterns requiring confirmatory infant follow-up.
    Interpretation and limitations
    High HbF is physiological; programme-specific patterns trigger confirmatory sampling and paediatric referral without adult percentage rules.
    • 2
    Ask the laboratory which variants share that analytical window and whether iron deficiency or donor cells could alter the apparent proportion.
  • 3Confirm consequential or discordant findings before assigning disease, offering irreversible treatment or calculating pregnancy risk.
    • 03Carrier counsellingTranslate two genotypes into choicesA carrier state is confirmed in someone planning or continuing a pregnancy.+
    1. 1Explain the individual's result, likely health implications and inheritance in plain language and offer a copy suitable for future clinicians.
    2. 2Arrange prompt partner testing and use both exact genotypes to explain the probability and possible severity for each pregnancy.
    3. 3Refer at-risk couples to screening, fetal medicine and clinical genetics for timely non-directive discussion of diagnostic and reproductive options.
    Carrier counselling explains that the carrier is usually healthy, avoids unnecessary restrictions and tests the reproductive partner before calculating fetal risk.
  • At-risk couples should receive genotype-specific, non-directive discussion of prenatal diagnosis, preimplantation testing and pregnancy or newborn pathways through the national screening programme.